BioCryst appoints J.P. Morgan executive to board

RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Steve Frank, a prominent figure in healthcare investment banking, to its board of directors. Frank, who is currently the chairman of global healthcare investment banking at J.P. Morgan, brings a wealth of experience to the biotechnology company, having led healthcare investment banking at Bear Stearns before its acquisition by J.P. Morgan in 2008.

Throughout his career, Frank has been recognized as a leading advisor to a range of healthcare firms, including those in pharmaceuticals, biotechnology, medical devices, and healthcare services. His expertise also extends to his time as an institutional investor, where he managed State Farm’s life science equity portfolio in the 1980s and early 1990s. Frank continues to hold the Chartered Financial Analyst accreditation.

Dr. Nancy Hutson, chair of the BioCryst board, noted Frank’s track record of guiding business development transactions and his strategic approach to capital allocation as key assets that will support BioCryst’s growth and profitability ambitions. Hutson highlighted BioCryst’s position in the biopharma industry, with a commercial product nearing $1 billion in peak sales, a robust financial standing, and a pipeline of potential therapies. The company’s strong financial health is reflected in its current ratio of 2.63, indicating ample liquidity to meet short-term obligations. According to InvestingPro data, BioCryst has achieved impressive revenue growth of 36% over the last twelve months.

Frank expressed his enthusiasm for joining the board during a pivotal period for BioCryst, which has successfully commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor. The company is also advancing a range of small-molecule and protein therapies in its pipeline.

In addition to his new role at BioCryst, Frank currently serves on the board of Precigen. He holds a B.S. from Illinois State University and an M.B.A. from the University of Chicago.

The announcement comes as BioCryst continues to navigate the complex landscape of developing and commercializing treatments for rare diseases. The company’s forward-looking statements in the press release indicate a focus on maintaining its commercialization plans for ORLADEYO and advancing its pipeline development. Recent InvestingPro analysis shows the stock trading near its 52-week high of $9.50, with analyst price targets ranging from $8 to $30 per share, suggesting significant potential upside. While these statements are subject to the usual risks and uncertainties inherent in the pharmaceutical industry, InvestingPro’s comprehensive analysis includes 12 additional key insights about BCRX’s financial health and market position, available through their Pro Research Report.

This news article is based on a press release statement from BioCryst Pharmaceuticals, Inc.

In other recent news, BioCryst Pharmaceuticals has reported several significant developments. The company received an Overweight rating from Cantor Fitzgerald, with a price target of $20, due to the strong market position of its drug Orladeyo, which is expected to achieve peak annual sales exceeding $1 billion. Citizens JMP also maintained a Market Outperform rating for BioCryst, setting a price target of $18, and highlighted the anticipated growth in Orladeyo’s sales, with projections reaching $800 million in U.S. revenue by 2029. Additionally, BioCryst is involved in a patent infringement lawsuit to protect Orladeyo against generic competition, seeking an injunction to prevent FDA approval of a competing drug until its patents expire in 2039.

The company is also undergoing an executive transition, as Chief Financial Officer Anthony Doyle announced his resignation, effective April 9, 2025. Jon P. Stonehouse, the current CEO, will serve as interim CFO while the company searches for a permanent successor. During this transition, Doyle will continue to provide consulting services to ensure a smooth handover. Furthermore, BioCryst’s development pipeline shows promise, with upcoming clinical data releases for treatments targeting Netherton syndrome and Diabetic Macular Edema. These recent developments reflect the company’s ongoing efforts to strengthen its market position and financial outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.